AstraZeneca (AZNCF) News Today $143.98 +0.73 (+0.51%) As of 05/27/2025 10:20 AM Eastern Add Compare Share Share Headlines Stock AnalysisChartDividendFinancialsHeadlinesOwnershipSEC FilingsShort InterestBuy This Stock AZNCF Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period AstraZeneca bladder cancer drug Imfinzi recommended for EU approvalMay 27 at 11:29 PM | lse.co.ukAstraZeneca (LSE:AZN) Gains EU Recommendation For Imfinzi in Bladder Cancer TreatmentMay 27 at 11:29 PM | finance.yahoo.comAptar Digital to use AstraZeneca’s AI algorithms for CKD detectionMay 23, 2025 | finance.yahoo.comAptar Digital Health Announces Licensing Agreement With AstraZeneca to Develop AI-Powered Screening AlgorithmsMay 22, 2025 | finance.yahoo.comAirsupra shows significant improvement in asthma treatment, AstraZeneca revealsMay 20, 2025 | au.investing.comAstraZeneca says Airsupra reduced severe asthma risk by 47%May 20, 2025 | finance.yahoo.comAstraZeneca (LSE:AZN) Reports Positive AIRSUPRA Results Reducing Severe Asthma RisksMay 20, 2025 | finance.yahoo.comAstraZeneca PLC: Acquisition of EsoBiotec completedMay 20, 2025 | finanznachrichten.deAstraZeneca completes EsoBiotec acquisition for up to USD1 billionMay 20, 2025 | lse.co.ukAstraZeneca means 'a road to death' in Latin?May 20, 2025 | msn.comAbu Dhabi, AstraZeneca forge strategic partnership to enhance COPD awareness, care in emirateMay 14, 2025 | msn.comAstraZeneca’s growth prospects are as attractive as ever. Keep buyingMay 14, 2025 | finance.yahoo.com21 analysts advised buy AstraZeneca shares in January – see what £10k invested then is worth nowMay 13, 2025 | msn.comAstraZeneca (LSE:AZN) Reports Positive Results From Phase III IMFINZI Trial In Bladder CancerMay 10, 2025 | uk.finance.yahoo.comUS court shuts down AstraZeneca's challenge to Medicare drug price planMay 10, 2025 | reuters.comAstraZeneca unveils new factory as part of multibillion-dollar investment in US manufacturingMay 6, 2025 | msn.comAstraZeneca's (LON:AZN) Earnings Offer More Than Meets The EyeMay 6, 2025 | finance.yahoo.comAZNCF Makes Bullish Cross Above Critical Moving AverageMay 2, 2025 | nasdaq.comAstraZeneca’s triple-combo triumphs in two Phase III asthma trialsMay 2, 2025 | finance.yahoo.comAstraZeneca's 'smoker's lung' therapy meets main goals of late-stage asthma trialsMay 2, 2025 | msn.comAstraZeneca asthma drug meets targets in phase 3 trialsMay 2, 2025 | lse.co.ukAstraZeneca's Breztri meets main goals of late-stage asthma trialsMay 2, 2025 | reuters.comImfinzi approval positions AstraZeneca at forefront of perioperative MIBCApril 30, 2025 | finance.yahoo.comAstraZeneca CFO Talks Tariffs, Forward Guidance, EarningsApril 30, 2025 | bloomberg.comAstraZeneca’s Soriot Warns US Against Trade Tariffs on MedicinesApril 29, 2025 | msn.comAstraZeneca has built resilient supply chains in the U.S. and China for years, doesn't expect much tariff impact, CEO saysApril 29, 2025 | msn.comAstraZeneca discontinues Truqap trial in castration-resistant prostate cancerApril 29, 2025 | msn.comAstraZeneca outlines $5B opportunity for oral PCSK9 inhibitor with Phase 3 trials in 2025April 29, 2025 | msn.comAstraZeneca's 'number 1 priority' is the US, CEO saysApril 29, 2025 | finance.yahoo.comAstraZeneca says potential US tariffs manageable, faces another China fineApril 29, 2025 | msn.comAstraZeneca CEO: Trump tariffs 'not material long term'April 29, 2025 | msn.comAstraZeneca doubles down on US manufacturing amid tariff threatApril 29, 2025 | msn.comAstraZeneca says potential US tariffs manageable; faces another China fineApril 29, 2025 | msn.comAstraZeneca affirms commitment to US manufacturing as profits riseApril 29, 2025 | ft.comAstraZeneca pushes EU to spend more on drugs amid Trump tariffs threatApril 25, 2025 | finance.yahoo.comAstraZeneca Earnings Expected to Rise With Focus on China -- Earnings PreviewApril 25, 2025 | marketwatch.comThe Zacks Analyst Blog Highlights Tempus AI, AstraZeneca, iRhythm Technologies and SOPHiA GENETICSApril 25, 2025 | finance.yahoo.comAstraZeneca CEO says Europe must invest more to protect its 'health sovereignty'April 24, 2025 | msn.comNew AstraZeneca breast cancer drug shows 'meaningful improvement' in survivability ratesApril 23, 2025 | msn.comAstraZeneca rallies Monday, outperforms marketApril 14, 2025 | marketwatch.comAstraZeneca’s oral breast cancer drug Truqap greenlit for NHS useApril 12, 2025 | msn.comBernstein Sticks to Its Buy Rating for AstraZeneca (AZN)April 9, 2025 | markets.businessinsider.comAstraZeneca (LSE:AZN) Gains EU Approval For Breast Cancer Treatment DATROWAYApril 9, 2025 | uk.finance.yahoo.comDaiichi Sankyo and AstraZeneca secure EU approval for DatrowayApril 9, 2025 | lse.co.ukAstraZeneca’s camizestrant gains momentum, but questions remain as first-line therapyApril 8, 2025 | finance.yahoo.comAstraZeneca’s AZD0780 Shows Promising Results in Cholesterol-Lowering Clinical TrialApril 7, 2025 | msn.comAstraZeneca slides Monday, underperforms marketApril 7, 2025 | marketwatch.comEC approves AstraZeneca’s Imfinzi combo for NSCLCApril 7, 2025 | finance.yahoo.comAstraZeneca gets EU approval for cancer treatments Enhertu and ImfinziApril 4, 2025 | lse.co.ukAstraZeneca (AZN) Receives a Buy from UBSApril 1, 2025 | markets.businessinsider.com Get AstraZeneca News Delivered to You Automatically Sign up to receive the latest news and ratings for AZNCF and its competitors with MarketBeat's FREE daily newsletter. Email Address AZNCF Media Mentions By Week AZNCF Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AZNCF News Sentiment▼0.021.03▲Average Medical News Sentiment AZNCF News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AZNCF Articles This Week▼45▲AZNCF Articles Average Week Get AstraZeneca News Delivered to You Automatically Sign up to receive the latest news and ratings for AZNCF and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies 4Front Ventures News Today Algernon Pharmaceuticals News Today Allstar Health Brands News Today Anew Medical News Today Arno Therapeutics News Today AVAX Technologies News Today BriaCell Therapeutics News Today Cannabis Global News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:AZNCF) was last updated on 5/28/2025 by MarketBeat.com Staff From Our PartnersTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...The Tomorrow Investor | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredWe’ve Entered the Most Bullish Phase of the CycleIt happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AstraZeneca PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share AstraZeneca With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy AZNCF Stock Free AZNCF Stock Alerts